Jefferies on Moderna (MRNA): 'Phase III Flu/Covid Combo looks good - could be on market in 2025'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $180.00 price target on Moderna (NASDAQ: MRNA).The analyst comments "Phase III ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
